Opportunities In RNA Therapeutics Market Overview:
Opportunities In RNA Therapeutics Market size was valued USD 16060 million in 2024 and is anticipated to reach USD 29506.22 million by 2032, at a CAGR of 7.9% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Opportunities In RNA Therapeutics Market Size 2024
USD 16060 million
Opportunities In RNA Therapeutics Market , CAGR
7.9%
Opportunities In RNA Therapeutics Market Size 2032
USD 29506.22 million
Opportunities In RNA Therapeutics Market Insights
Market growth is driven by rising clinical success of mRNA, siRNA, and antisense therapies, increasing investment in delivery technologies, and growing focus on genetic, oncology, and rare disease indications.
Key market trends include rapid evolution of RNA delivery platforms, increasing use of AI in RNA design, expansion into non-infectious disease areas, and higher interest in repeat-dosing and chronic RNA therapies.
Competitive dynamics are shaped by established pharmaceutical companies and specialized biotech firms competing on pipeline depth, translational efficiency, manufacturing scalability, and strategic partnerships.
Regionally, North America leads with an exact 42% market share, while mRNA-based therapeutics dominate by segment, followed by siRNA and antisense platforms, supported by broad clinical applicability and scalable development models.Top of Form
Opportunities In RNA Therapeutics Market Segmentation Analysis:
By Product
By product, vaccines represent the dominant sub-segment in the Opportunities in RNA Therapeutics Market, accounting for approximately 54% market share, driven by rapid platform scalability, strong immunogenic performance, and proven clinical deployment across large populations. mRNA vaccine platforms benefit from shorter development timelines, standardized manufacturing, and rapid antigen reprogramming, supporting outbreak responsiveness and lifecycle extensions. In contrast, RNA-based drugs are expanding steadily, supported by advances in delivery systems, improved molecular stability, and growing acceptance for chronic and rare disease treatment. However, higher clinical complexity and longer regulatory pathways continue to position vaccines as the leading revenue contributor.
For instance, Arrakis Therapeutics has demonstrated direct RNA-targeting small-molecule platforms capable of selectively binding structured RNA motifs with nanomolar binding affinities below 50 nM, while achieving reproducible synthesis yields exceeding 99% chemical purity across multiple RNA targets, highlighting the technological maturity supporting scalable RNA-focused product development.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
By type, mRNA therapeutics dominate the market with an estimated 48% share, supported by high translational efficiency, modular design, and broad applicability across vaccines and protein-replacement therapies. Strong progress in lipid nanoparticle delivery, codon optimization, and scalable GMP manufacturing reinforces this leadership. Antisense oligonucleotides (ASOs) and siRNA/RNAi therapeutics follow, driven by their high target specificity and gene-silencing precision in rare and genetic disorders. While other RNA types remain in early clinical stages, expanding pipeline diversity and improved intracellular delivery technologies continue to strengthen overall segment competitiveness.
For instance, F. Hoffmann-La Roche Ltd has advanced its antisense platform through the development of tominersen for Huntington’s disease. In clinical studies, this candidate has demonstrated mean reductions of mutant huntingtin (mHTT) protein in cerebrospinal fluid exceeding 40% from baseline, while achieving oligonucleotide synthesis batch purities above 98% under GMP conditions.
By Indication
By indication, infectious diseases hold the leading position with around 46% market share, fueled by global immunization programs, pandemic preparedness strategies, and rapid regulatory mobilization for RNA-based solutions. RNA platforms enable swift antigen updates and scalable production, ensuring sustained dominance in this segment. Hereditary and genetic diseases represent the fastest-growing opportunity, driven by unmet medical needs and the suitability of RNA modalities for gene-level intervention. Autoimmune and other indications are gaining traction as delivery precision and safety profiles improve, broadening the therapeutic scope of RNA technologies.
Key Growth Drivers
Rising Clinical Validation Across Diverse Indications
The RNA therapeutics market benefits strongly from expanding clinical validation across oncology, infectious diseases, rare genetic disorders, and autoimmune conditions. Increasing numbers of late-stage clinical trials demonstrate improved efficacy, durability, and safety of RNA-based modalities, strengthening physician and regulator confidence. Regulatory approvals of RNA-based products have established clearer development pathways, reducing translational risk for pipeline candidates. As clinical datasets mature, RNA therapeutics gain broader acceptance as viable alternatives or complements to small molecules and biologics, accelerating investment flows and expanding addressable patient populations across both chronic and acute disease segments.
For instance, Arrakis demonstrated lead rSM candidates for Myotonic Dystrophy Type 1 (DM1) that selectively bind to pathogenic CUG repeats with low-nanomolar affinities (below 50 nM).
Advancements in Delivery Technologies
Continuous innovation in RNA delivery systems remains a central growth driver. Next-generation lipid nanoparticles, polymer-based carriers, and ligand-targeted delivery platforms significantly enhance tissue specificity, intracellular uptake, and RNA stability. These advances reduce off-target effects and enable lower dosing, improving therapeutic indices. Enhanced delivery capabilities also unlock new indications previously limited by poor biodistribution or toxicity. As delivery efficiency improves, RNA therapeutics increasingly transition from niche or injectable-only applications toward more scalable, repeat-dosing, and potentially localized treatment paradigms, broadening commercial and clinical viability.
For instance, PTC Therapeutics, Inc. has validated its proprietary oral RNA-targeted delivery and translational control technologies through its splicing modulator platforms, where compounds such as risdiplam demonstrated sustained increases in full-length SMN protein levels above 2.5-fold from baseline in patient-derived cellular systems, achieved oral bioavailability exceeding 90 units in preclinical models, and maintained consistent central nervous system exposure across dosing intervals, as documented in company regulatory filings and peer-reviewed clinical publications.
Strong Investment and Strategic Partnerships
Sustained capital inflows from venture funding, public markets, and strategic pharmaceutical partnerships support rapid innovation in RNA therapeutics. Large biopharmaceutical companies increasingly collaborate with specialized RNA platform developers to access proprietary chemistries, delivery systems, and manufacturing expertise. These alliances accelerate development timelines, de-risk early-stage research, and enable global commercialization. Additionally, government funding and pandemic preparedness initiatives continue to support RNA platform scalability, reinforcing long-term infrastructure and manufacturing capacity that benefits both therapeutic and prophylactic RNA applications.
Key Trends & Opportunities
Expansion Beyond Vaccines into Therapeutic Applications
A major opportunity lies in the diversification of RNA technologies beyond vaccines into protein replacement, gene silencing, and immune modulation therapies. mRNA, siRNA, and antisense platforms are increasingly applied to chronic and rare diseases with high unmet medical needs. This shift enables RNA therapeutics to address indications unsuitable for traditional biologics due to intracellular targets. As pipelines diversify, developers can pursue differentiated pricing strategies and longer treatment durations, supporting more stable revenue models and expanding long-term market opportunities.
For instance, Anima Biotech Inc. has leveraged its mRNA Lightning™ platform to train Visual Biology Models on over 2 billion proprietary cellular pathway images to computationally identify and prioritize potential mRNA-modulating targets with high biological relevance, and through its Lightning AI program has already identified 20 distinct therapeutic candidates across neurological, oncological, and immunological indications in preclinical studies, demonstrating measurable modulation of target biology in live cell assays, as reported by the company.
Personalized and Precision Medicine Integration
RNA therapeutics align closely with precision medicine approaches due to their modular design and rapid customization potential. Advances in genomic profiling and biomarker identification enable patient-specific RNA constructs and targeted treatment regimens. This trend creates opportunities for companion diagnostics, adaptive trial designs, and niche therapies for genetically defined populations. As healthcare systems increasingly prioritize personalized interventions, RNA-based platforms are well positioned to support tailored therapies with faster development cycles and higher clinical relevance.
For instance, Accent Therapeutics’ lead clinical programs TX-559, a selective DHX9 helicase inhibitor, and ATX-295, a KIF18A mitotic motor protein inhibitor are each being evaluated in Phase 1/2 clinical trials with identifiers NCT06625515 and NCT06799065.
Manufacturing Scale-Up and Platform Standardization
Improving standardization of RNA synthesis, formulation, and quality control creates opportunities for cost reduction and faster commercialization. Platform-based manufacturing allows multiple candidates to share common production infrastructure, improving operational efficiency. As contract manufacturing capacity expands globally, smaller developers gain access to GMP-grade production without heavy capital investment. This trend lowers entry barriers, supports pipeline diversification, and accelerates time-to-market for novel RNA therapeutics across indications.
Key Challenges
Delivery, Stability, and Long-Term Safety Concerns
Despite progress, RNA therapeutics still face challenges related to in vivo stability, immune activation, and long-term safety with repeated dosing. Some delivery systems trigger inflammatory responses or exhibit limited tissue specificity, constraining chronic-use applications. Long-term exposure data remain limited for several RNA modalities, creating regulatory and clinical uncertainties. Addressing these issues requires continued investment in chemistry optimization, delivery innovation, and extended safety studies, which can lengthen development timelines and increase costs.
Regulatory Complexity and Manufacturing Scalability
Regulatory frameworks for RNA therapeutics continue to evolve, with varying global requirements for characterization, potency assays, and long-term monitoring. Navigating these complexities can delay approvals, particularly for novel delivery systems or first-in-class mechanisms. Additionally, large-scale manufacturing demands stringent control over raw materials, batch consistency, and cold-chain logistics. Any disruption in supply chains or quality control can significantly impact development and commercialization, posing operational risks for emerging and established RNA therapy developers alike.
Regional Analysis
North America
North America dominates the Opportunities in RNA Therapeutics Market with an estimated 42% market share, driven by strong clinical research infrastructure, early adoption of novel RNA modalities, and a favorable regulatory environment. The region benefits from high concentrations of biotechnology firms, advanced manufacturing capabilities for mRNA and oligonucleotide therapeutics, and robust funding from both public and private sources. The United States leads regional growth due to extensive clinical trial activity, accelerated FDA review pathways, and strong collaborations between academia and industry. Continued investment in next-generation RNA platforms, including mRNA, siRNA, and antisense therapies, sustains North America’s leadership position.
Europe
Europe accounts for approximately 27% market share, supported by a strong academic research base, expanding biotech ecosystems, and coordinated regulatory frameworks across major economies. Countries such as Germany, the UK, and France drive adoption through public–private partnerships, government-funded translational research programs, and increasing clinical trial participation. The European Medicines Agency’s structured approval pathways and emphasis on advanced therapies encourage RNA drug development. Growth is further reinforced by rising investments in rare disease and oncology RNA pipelines, alongside increasing manufacturing capacity for GMP-grade RNA products across Western and Northern Europe.
Asia-Pacific
Asia-Pacific holds nearly 22% market share and represents the fastest-growing regional opportunity in RNA therapeutics. Rapid expansion of biotechnology hubs in China, Japan, South Korea, and India, combined with increasing government support for domestic biopharmaceutical innovation, fuels market growth. The region benefits from improving clinical trial infrastructure, large patient populations, and growing adoption of mRNA and RNAi platforms beyond infectious diseases. Strategic investments in local RNA manufacturing, technology transfer agreements, and cost-efficient development capabilities position Asia-Pacific as a key growth engine over the forecast period.
Latin America
Latin America contributes around 5% market share, with growth driven by gradual improvements in healthcare infrastructure and increasing participation in multinational clinical trials. Brazil and Mexico lead regional adoption due to expanding regulatory capabilities and rising interest in advanced biologics for infectious and chronic diseases. Although local RNA manufacturing remains limited, partnerships with global pharmaceutical companies enable technology access and market entry. Increasing government focus on pandemic preparedness, vaccination programs, and rare disease treatment supports steady uptake of RNA therapeutics across select Latin American markets.
Middle East & Africa
The Middle East & Africa region accounts for roughly 4% market share, reflecting an early-stage but emerging opportunity for RNA therapeutics. Growth is supported by increasing healthcare investments in Gulf Cooperation Council countries, expanding biotechnology initiatives, and rising awareness of advanced therapeutic modalities. While clinical development and manufacturing capabilities remain nascent, regional governments are investing in precision medicine, genomic research, and strategic partnerships with global biopharma companies. Gradual regulatory modernization and improving access to innovative therapies are expected to support long-term RNA therapeutics adoption across the region.
Opportunities In RNA Therapeutics Market Segmentations:
By Product:
Vaccines
Drugs
By Type:
mRNA therapeutics
Antisense oligonucleotide (ASO) therapeutics
By Indication:
Infectious diseases
Hereditary/genetic diseases
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Competitive Landscape
The competitive landscape of the Opportunities in RNA Therapeutics Market players such as Arrakis Therapeutics, F. Hoffmann-La Roche Ltd, Expansion Therapeutics, PTC Therapeutics, Inc., Anima Biotech Inc., Les Laboratoires Servier, Accent Therapeutics, Ribometrix, AstraZeneca, Epics Therapeutics. the Opportunities in RNA Therapeutics Market is highly innovation-driven, marked by intense focus on novel RNA-targeting mechanisms and platform differentiation. Market participants compete by advancing proprietary technologies that enable selective modulation of RNA structure, translation, splicing, and epitranscriptomic regulation, expanding therapeutic reach beyond traditional protein-centric approaches. Strategic collaborations between biotechnology innovators and large pharmaceutical companies play a critical role in accelerating discovery, clinical validation, and global commercialization. Competition increasingly centers on pipeline depth, target selectivity, and the ability to address genetically defined and previously undruggable diseases. Strong intellectual property portfolios, access to advanced RNA analytics, and scalable manufacturing capabilities further influence competitive positioning. As clinical pipelines mature, companies that successfully demonstrate safety, durability of response, and translational efficiency are expected to gain a sustainable advantage, reinforcing a dynamic and rapidly evolving competitive environment.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In August 2025, Skyhawk Therapeutics entered a strategic collaboration with Merck KGaA, Darmstadt, Germany, to discover RNA-targeting small molecules for neurological disorders, with Skyhawk leading discovery and preclinical development.
In March 2025, Arrakis Therapeutics Presents Data Highlighting Progress of Oral RNA targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1) at the Muscular Dystrophy Association (MDA) conference in Dallas, Texas.
In February 2025, Bio-Rad Laboratories offered to acquire Stilla Technologies, France and U.S.-based developer of next-generation digital PCR solutions, aiming to complement its portfolio and accelerate digital PCR innovation globally.
Report Coverage
The research report offers an in-depth analysis based on Product,Type, Indicationand Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
RNA therapeutics will expand beyond infectious diseases into oncology, neurology, cardiovascular, and rare genetic disorders.
Advancements in delivery technologies will significantly improve tissue targeting, cellular uptake, and therapeutic durability.
Next-generation RNA modalities, including circular RNA and self-amplifying RNA, will gain stronger clinical traction.
Integration of AI and computational biology will accelerate RNA target identification and sequence optimization.
Epitranscriptomic regulation will emerge as a major therapeutic focus, enabling precise control of gene expression.
Manufacturing scalability and process standardization will improve global supply reliability and cost efficiency.
Regulatory frameworks will continue to mature, supporting faster approvals for well-validated RNA platforms.
Strategic partnerships between biotech innovators and large pharmaceutical companies will intensify.
Personalized and precision RNA therapies will see higher adoption in genetically defined patient populations.
Long-term growth will be reinforced by expanding clinical evidence demonstrating safety, efficacy, and repeat dosing feasibility.
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope 2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology 3. Executive Summary 4. Introduction
4.1. Overview
4.2. Key Industry Trends 5. Global Opportunities in RNA Therapeutics Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast 6. Market Breakup by Product
6.1. Vaccines
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. Drugs
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity 7. Market Breakup by Type
7.1. mRNA Therapeutics
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. Antisense Oligonucleotide (ASO) Therapeutics
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity 8. Market Breakup by Indication
8.1. Infectious Diseases
8.1.1. Market Trends
8.1.2. Market Forecast
8.1.3. Revenue Share
8.1.4. Revenue Growth Opportunity
8.2. Hereditary/Genetic Diseases
8.2.1. Market Trends
8.2.2. Market Forecast
8.2.3. Revenue Share
8.2.4. Revenue Growth Opportunity 9. Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.1.1. Market Trends
9.1.1.2. Market Forecast
9.1.2. Canada
9.1.2.1. Market Trends
9.1.2.2. Market Forecast
9.2. Asia-Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia
9.2.6. Indonesia
9.2.7. Others
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. United Kingdom
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Others
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Others
9.5. Middle East and Africa
9.5.1. Market Trends
9.5.2. Market Breakup by Country
9.5.3. Market Forecast 10. SWOT Analysis
10.1. Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats 11. Value Chain Analysis 12. Porter’s Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes 13. Price Analysis 14. Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. Arrakis Therapeutics
14.3.2. F. Hoffmann-La Roche Ltd
14.3.3. Expansion Therapeutics
14.3.4. PTC Therapeutics, Inc.
14.3.5. Anima Biotech Inc.
14.3.6. LES LABORATOIRES SERVIER
14.3.7. ACCENT Therapeutics
14.3.8. Ribometrix
14.3.9. AstraZeneca
14.3.10. Epics Therapeutics 15. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for Opportunities In RNA Therapeutics Market, and what is its projected size in 2032?
The market was valued at USD 16,060 million in 2024 and is projected to reach USD 29,506.22 million by 2032, reflecting strong long-term expansion.
At what Compound Annual Growth Rate is the Opportunities In RNA Therapeutics Market projected to grow between 2024 and 2032?
The market is expected to grow at a CAGR of 7.9% during the forecast period from 2025 to 2032.
Which Opportunities In RNA Therapeutics Market segment held the largest share in 2024?
The vaccines segment held the largest share, driven by scalable mRNA platforms, rapid development timelines, and broad immunization deployment.
What are the primary factors fueling the growth of the Opportunities In RNA Therapeutics Market?
Key growth drivers include expanding clinical validation, advancements in RNA delivery technologies, and strong investment and strategic partnerships.
Who are the leading companies in the Opportunities In RNA Therapeutics Market?
Leading players include a mix of global pharmaceutical companies and specialized RNA-focused biotechnology innovators with strong pipelines and platforms.
Which region commanded the largest share of the Opportunities In RNA Therapeutics Market in 2024?
North America led the market with an exact 42% share, supported by advanced research infrastructure and early adoption of RNA technologies.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
Oral Solid Dosage Manufacturing Market size was valued USD 38629 million in 2024 and is anticipated to reach USD 60644.9 million by 2032, at a CAGR of 5.8% during the forecast period.
Nanoparticle Formulation Market size was valued USD 8589 million in 2024 and is anticipated to reach USD 16863.73 million by 2032, at a CAGR of 8.8% during the forecast period.
Bile Duct Cancer Treatment Market size was valued USD 3880 million in 2024 and is anticipated to reach USD 7235.44 million by 2032, at a CAGR of 8.1% during the forecast period.
3D Printing for Personalized Healthcare Market was valued at USD 1627 million in 2024 and is anticipated to reach USD 6506.74 million by 2032, growing at a CAGR of 18.92 % during the forecast period.
Automated Cell Counter Market size was valued USD 6830 million in 2024 and is anticipated to reach USD 10229.5 million by 2032, at a CAGR of 5.18% during the forecast period.
Autologous Conditioned Plasma (ACP) Market size was valued USD 584 million in 2024 and is anticipated to reach USD 1366.31 million by 2032, at a CAGR of 11.2% during the forecast period.
Autogenous Vaccine Market size was valued USD 465 million in 2024 and is anticipated to reach USD 810.46 million by 2032, at a CAGR of 7.2% during the forecast period.
Asia-Pacific Breast Implants Market size was valued USD 396 million in 2024 and is anticipated to reach USD 752.29 million by 2032, at a CAGR of 8.34% during the forecast period.
Animal Stem Cell Therapy Market size was valued USD 772 million in 2024 and is anticipated to reach USD 1584 million by 2032, at a CAGR of 9.4% during the forecast period.
The Novel Antibody Therapies Market was valued at USD 313,459 million and is projected to reach USD 765,093.7 million by 2032, expanding at a robust compound annual growth rate (CAGR) of 11.8% over the forecast period.
The global combination therapies in aesthetics market was valued at USD 3,690 million in 2024 and is projected to reach USD 6,880.69 million by 2032, expanding at a compound annual growth rate (CAGR) of 8.1% during the forecast period.
The commercial aquaculture vaccines market was valued at USD 471 million in 2024 and is projected to reach USD 845.93 million by 2032, expanding at a compound annual growth rate (CAGR) of 7.6% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
